Alpha 2.0
Login Register
» Articles » PMID: 21321149

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam Against Enterobacteriaceae, Pseudomonas Aeruginosa, and Bacteroides Fragilis Strains Having Various Resistance Phenotypes

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 2011 Feb 16
PMID 21321149
Citations 47
Authors
Helio S Sader
Paul R Rhomberg
David J Farrell
Ronald N Jones
Affiliations
Soon will be listed here.
Abstract

CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis. CXA-201 was 2- to 32-fold more active than ceftazidime and piperacillin-tazobactam against ceftazidime-resistant Enterobacteriaceae species but less active than cefepime for some species. CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains.

Citing Articles

activity of cefiderocol against European and spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.

Santerre Henriksen A, Jeannot K, Oliver A, Perry J, Pletz M, Stefani S Microbiol Spectr. 2024; 12(4):e0383623.

PMID: 38483164 PMC: 10986614. DOI: 10.1128/spectrum.03836-23.

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report.

Ibe Y, Kakizaki R, Inamura H, Ishigo T, Fujiya Y, Inoue H J Pharm Health Care Sci. 2023; 9(1):25.

PMID: 37550794 PMC: 10408163. DOI: 10.1186/s40780-023-00294-x.

A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.

Saeed M, Gillani S, Mahmood R, Vippadapu P, Hussain M, Rathore H Biomed Res Int. 2022; 2022:1639114.

PMID: 35978637 PMC: 9377909. DOI: 10.1155/2022/1639114.

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.

Gorham J, Taccone F, Hites M Antibiotics (Basel). 2022; 11(5).

PMID: 35625190 PMC: 9137536. DOI: 10.3390/antibiotics11050546.

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.

Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455461 PMC: 9028825. DOI: 10.3390/ph15040463.

References
1.
Livermore D, Mushtaq S, Ge Y, Warner M . Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009; 34(5):402-6. DOI: 10.1016/j.ijantimicag.2009.03.021. View
2.
Bulik C, Christensen H, Nicolau D . In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother. 2009; 54(1):557-9. PMC: 2798502. DOI: 10.1128/AAC.00912-09. View
3.
Castanheira M, Sader H, Jones R . Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist. 2010; 16(1):61-5. DOI: 10.1089/mdr.2009.0031. View
4.
Moya B, Zamorano L, Juan C, Perez J, Ge Y, Oliver A . Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010; 54(3):1213-7. PMC: 2825979. DOI: 10.1128/AAC.01104-09. View
5.
Livermore D, Mushtaq S, Ge Y . Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010; 65(9):1972-4. DOI: 10.1093/jac/dkq248. View